| Literature DB >> 27042656 |
Jingnan Xu1, Zhuo Song2, Qiujun Guo1, Jie Li3.
Abstract
The interaction of tumor cells with the microenvironment is like a relationship between the "seeds" and "soil," which is a hotspot in recent cancer research. Targeting at tumor microenvironment as well as tumor cells has become a new strategy for cancer treatment. Conventional cancer treatments mostly focused on single targets or single mechanism (the seeds or part of the soil); few researches intervened in the whole tumor microenvironment and achieved ideal therapeutic effect as expected. Traditional Chinese medicine displays a broad range of biological effects, and increasing evidence has shown that it may relate with synergistic effect on regulating tumor microenvironment and cancer cells. Based on literature review and our previous studies, we summarize the synergistic effect and the molecular mechanisms of traditional Chinese medicine on regulating tumor microenvironment and cancer cells.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27042656 PMCID: PMC4793102 DOI: 10.1155/2016/1490738
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Several clinical studies have confirmed the effectiveness of TCM in cancer treatment.
| Drug | Type of cancer | Phase | Method | Interventions | Outcomes | Cite | |
|---|---|---|---|---|---|---|---|
| Control group | Treatment group | ||||||
| Ginsenoside Rg3 | NSCLC | Clinical stages II/IIIa, postoperative patients | RCT, not blinded | Chemotherapy (NP/CE/GP) | Shenyi capsule, or it combines with chemotherapy | Improves the life span of patients | [ |
|
| |||||||
| Cantharidinate | NSCLC | Middle-late stage | RCT, not blinded | GP | Combines with cantharidinate | Improves clinical effects and life quality, lowers the toxic/adverse effects of chemotherapy | [ |
|
| |||||||
| Astragalus polysaccharide | NSCLC | Clinical stages IIIB or IV advanced disease | RCT, not blinded | Vinorelbine and cisplatin | Combines with APS | Improves patients' QOL | [ |
|
| |||||||
| Xiaoaiping | Breast cancer | Neoadjuvant chemotherapy | RCT, not blinded | TEC neoadjuvant chemotherapy | Combines with Xiaoaiping injection | Significantly enhances short-term and long-term efficacies of neoadjuvant chemotherapy | [ |
|
| |||||||
| Atractylenolide I | Gastric cancer | Cachexia patients | RCT, not blinded | Nutritional supplementation | Adds atractylenolide I | Improves appetite and KPS status and decreases PIF positive rate | [ |
|
| |||||||
| Jianpi Huayu therapy | Hepatocellular carcinoma | Firstly treated patients | RCT, not blinded | Hepatectomy and conventional western medicine treatment | Combines with Jianpi Huayu therapy | Reduces postoperative recurrence and metastasis, improves DFS and OS | [ |
|
| |||||||
| Huachansu | Gallbladder carcinoma | Locally advanced or metastatic | Not RCT, not blinded, continued until termination events | Gemcitabine-oxaliplatin | Combines with Huachansu injection | Makes chemotherapy well tolerated and improves the QOL of patients | [ |
|
| |||||||
| Curcumin | Colorectal cancer | Liver metastases | Escalation trial, 12 cycles of chemotherapy | FOLFOX chemotherapy | Combines with curcumin | Prolongs median PFS and improves treatment response | [ |
|
| |||||||
| Compound Zhebei granules | Acute leukemia | Posttreatment and defined as refractory | RCT, double-blind and multicentral concurrent control, 14 days | Multiple chemotherapeutic schemes | Combines with compound Zhebei granules | Increases the clinical remission rate | [ |
Different mechanisms and channels of TCM inhibiting the growth of tumor cells.
| Cancer | Drug | Main mechanisms | Main channels | Related biomarkers | Cite |
|---|---|---|---|---|---|
| Lung cancer | Xiaoji decoction | Inhibits proliferation and induces apoptosis | Signaling Akt pathway | BAD ↑, caspase-9 ↑ | [ |
|
| |||||
| Lung cancer | Oxymatrine | Induces apoptosis | Bcl-2 family | Bax ↑ and Bcl-2 ↓ | [ |
|
| |||||
| Esophageal carcinoma | Soups of | Inhibits proliferation and induces apoptosis | Ki-67, Bcl-2 family | Bax ↑ and Ki-67, Bcl-2 ↓ | [ |
|
| |||||
| Esophageal carcinoma |
| Inhibits proliferation | MAPK signaling pathway | cyclinD1, p-ERK ↓ | [ |
|
| |||||
| Gastric cancer | Sanpi Pingwei formula | Inhibits proliferation and induces apoptosis | Bax, p53, and Bcl-2 | Bax, p53 ↑ and Bcl-2 ↓ | [ |
|
| |||||
| Gastric cancer | Arsenic sulfide | Induces apoptosis | p53 | Bax, MDM2 ↑ and Bcl-2 ↓ | [ |
|
| |||||
| Colorectal cancer | Jianpi Huayu decoction | Inhibits proliferation and induces apoptosis | G0/G1-phase cell cycle arrest, caspase-cascade activation and execution | p27 ↑ and cyclinD1, cyclinD2, cyclinD3, cyclinE1, CDK4, CDK6, CDK2 ↓ | [ |
|
| |||||
| Colorectal cancer | Emodin | Induces apoptosis | Bcl-2 family | Bax ↑ and Bcl-2 ↓ | [ |
|
| |||||
| Live cancer | Bufalin | Inhibits proliferation and triggers autophagy | G2/M phase arrest and JNK pathway | TNF, BECN-1, MAPK, ATG8 ↑ and Bcl-2, Bid ↓ | [ |
|
| |||||
| Breast cancer | San-Zhong-Kui-Jian-Tang | Inhibits proliferation and induces apoptosis | p21/WAF1 levels, p53, Bcl-2 family | p21, Bax, Bak ↑ and cyclinD1, cyclinD2, Bcl-2 ↓ | [ |
|
| |||||
| Ovarian cancer | Pien Tze Huang | Inhibits proliferation | AKT-mTOR pathway | AKT, (p)-AKT, mTOR p-mTOR proteins, CDK4, CDK6 ↓ | [ |
Figure 1The confirmed mechanism of TCM on tumor cells and microenvironment. TCM can inhibit “seeds” and regulate “soil” to suppress tumor development and recurrence via diverse ways. The mechanism of TCM inhibiting tumor “seeds” includes inhibiting growth, invasion, metastasis of cancer cells, and reversing immunosuppressive phenotypes and drug resistance. Meanwhile, TCM regulates “soil” through remodeling immunosuppressive microenvironment, hypoxia microenvironment, and angiogenesis/lymphangiogenesis, and ECM are also reversed when treated by TCM.